Johnson & Johnson explains how targeted oral peptides reach tissue targets
A company scientist says modified oral peptides combine small-molecule distribution with the target specificity of large protein drugs.
PR
By Priya Raman · Science Reporter
Oct 5 11:38 ETSource: Johnson & Johnson
The wire
- 01Johnson & Johnson's Beverly Knight describes targeted oral peptides as a middle category between small molecules and protein drugs, engineered to survive the GI tract and be absorbed.
- 02Oral delivery is the central technical barrier in peptide therapeutics, and the company distinguishes these approved medicines from peptide products sold online or at wellness clinics.
- 03This is company-published explanatory content, not new data; no specific compound, trial or approval timeline is named.
From the source
Read at jnj.comThe science behind targeted oral peptides
At their most basic, peptides are short chains or arrangements of amino acids, which are the building blocks of protein. Peptides have multiple normal biological roles: They provide amino acids for building and repairing muscle, act as hormones and signaling molecules, form the building blocks of enzymes and contribute to immune function.
